18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer:: High impact in patients with atelectasis

被引:250
作者
Nestle, U
Walter, K
Schmidt, S
Licht, N
Nieder, C
Motaref, B
Hellwig, D
Niewald, M
Ukena, D
Kirsch, CM
Sybrecht, GW
Schnabel, K
机构
[1] Univ Saarland, Med Ctr, Dept Radiotherapy, D-6650 Homburg, Germany
[2] Univ Saarland, Med Ctr, Dept Nucl Med, D-6650 Homburg, Germany
[3] Univ Saarland, Med Ctr, Dept Internal Med Pneumol 5, D-6650 Homburg, Germany
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1999年 / 44卷 / 03期
关键词
lung cancer; PET; radiotherapy; planning; atelectasis;
D O I
10.1016/S0360-3016(99)00061-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: F-18-deoxyglucose positron emission tomography (FDG-PET) is increasingly applied in the staging of lung cancer (LC). This study analyzes the potential contribution of PET in radiotherapy planning for LC with special respect to tumor-associated atelectasis. Methods and Materials: Thirty-four patients with histologically confirmed LC, who had been examined by PET during pretreatment staging, were included. All were irradiated after CT-based therapy planning with anterior/posterior (AP) portals encompassing the primary tumor and the mediastinum (CT portals, CP). The result of the PET examination was unknown in treatment planning. In retrospect, a PET portal (PP) was delineated and compared with the CP. Results: In 12/34 cases, the shape and/or size of the portals were changed, primarily (n = 10) the size of the fields was reduced. The median area of CP was 182 cm(2) versus 167 cm(2) of PP. Seventeen of 34 patients had dys- or atelectasis caused by a central primary tumor. In these cases, differences between CP and PP were significantly more frequent than in the other patients (8/17 vs. 3/17, p = 0.03). Conclusion: In this retrospective analysis, the information provided by FDG-PET would have contributed to a substantial reduction of the size of radiotherapy portals. This applies particularly for patients with tumor-associated dys- or atelectasis. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:593 / 597
页数:5
相关论文
共 20 条
[1]   Staging of the mediastinum: Value of positron emission tomography imaging in non-small cell lung cancer [J].
Bury, T ;
Paulus, P ;
Dowlati, A ;
Corhay, JL ;
Weber, T ;
Ghaye, B ;
Schoffers, J ;
Limet, R ;
Albert, A ;
Rigo, P ;
Radermecker, M .
EUROPEAN RESPIRATORY JOURNAL, 1996, 9 (12) :2560-2564
[2]  
DEBOIS M, 1998, RADIOTHER ONCOL, V48, pS13
[3]   What margins should be added to the clinical target volume in radiotherapy treatment planning for lung cancer? [J].
Ekberg, L ;
Holmberg, O ;
Wittgren, L ;
Bjelkengren, G ;
Landberg, T .
RADIOTHERAPY AND ONCOLOGY, 1998, 48 (01) :71-77
[4]  
Emami Bahman, 1996, International Journal of Radiation Oncology Biology Physics, V36, P209, DOI 10.1016/S0360-3016(97)85443-0
[5]   Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer [J].
Graham, MV ;
Purdy, JA ;
Emami, B ;
Matthews, JW ;
Harms, WB .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 33 (05) :993-1000
[6]   The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas [J].
Gross, MW ;
Weber, WA ;
Feldmann, HJ ;
Bartenstein, P ;
Schwaiger, M ;
Molls, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (05) :989-995
[7]   Lymph node staging in non-small cell lung cancer: Evaluation by [F-18]FDG positron emission tomography (PET) [J].
Guhlmann, A ;
Storck, M ;
Kotzerke, J ;
Moog, F ;
SunderPlassmann, L ;
Reske, SN .
THORAX, 1997, 52 (05) :438-441
[8]  
GUPTA NC, 1996, J NUCL MED, V19, P416
[9]   Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: Preliminary findings [J].
Hebert, ME ;
Lowe, VJ ;
Hoffman, JM ;
Patz, EF ;
Anscher, MS .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (04) :416-421
[10]   The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer [J].
Kiffer, JD ;
Berlangieri, SU ;
Scott, AM ;
Quong, G ;
Feigen, M ;
Schumer, W ;
Clarke, CP ;
Knight, SR ;
Daniel, FJ .
LUNG CANCER, 1998, 19 (03) :167-177